Background: Mavacamten, a novel cardiac myosin inhibitor, has emerged as a targeted therapy for obstructive hypertrophic cardiomyopathy (HCM). While clinical trials have demonstrated its efficacy, ...

Extreme heat events have been demonstrated to increase emergency department (ED) visits, hospitalizations, and mortality, but evidence of their impacts on the associated costs and on outpatient use is ...